3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Triple Negative Breast Neoplasms
8
Breast Neoplasms
8
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Transitional Cell
2
Urinary Bladder Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasm Metastasis
1
Lung Diseases
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Endometrial Neoplasms
1
Interventions
sacituzumab govitecan
1
amrubicin
1
Topotecan
1
PM 01183
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
×
sacituzumab govitecan
×
Clear all
NCT06801834
2026-05-20
EVOKE-SCLC-04
Gilead Sciences
Phase 3
Recruiting
695 enrolled